Displaying One Session

ITM Isotopen Technologien München AG - A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy (ID 102)

Time
10:30 - 12:00

Welcome & Introduction (ID 4655)

Changes in the Incidence and Prevalence of NETs – Impact of New Diagnostic Paradigms (ID 4656)

The Evolution of Guidelines for the Treatment of NETs (ID 4657)

The Role of Targeted Radionuclide Therapy in Clinical Trials (ID 4658)

Questions & Answers (ID 4659)

Conclusion (ID 4660)